Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Autism
FollowWhat is new in Autism research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- ArbaclofenPhase 3 · NCT07655115
- BumetanidePhase 3 · NCT04766177
- CM-ATPhase 3 · NCT02649959
- KarX-ECPhase 3 · NCT07284745 · NCT07424404 · NCT07285798
- KarXTPhase 3 · NCT07284745 · NCT07424404 · NCT07285798
- KarXT + KarX-EC Matching PlaceboPhase 3 · NCT07284745 · NCT07285798
- LumateperonePhase 3 · NCT06229210
- Lumateperone high dosePhase 3 · NCT06706674 · NCT06690398
- Lumateperone low dosePhase 3 · NCT06706674 · NCT06690398
- NTI164Phase 3 · NCT07257939
- CodabakalnerPhase 2/3 · NCT07439510
- Everolimus blinded oral capsulesPhase 2/3 · NCT07218575
- N acetyl cysteinePhase 2/3 · NCT05664789
- N-AcetylcysteinePhase 2/3 · NCT04278898 · NCT05494398
- 1. Intranasal oxytocin sprayPhase 2 · NCT05754073
- 2. Intranasal placebo sprayPhase 2 · NCT05754073
- 3. Intranasal Oxytocin sprayPhase 2 · NCT05754073
- ATRAPhase 2 · NCT07079696
- Autologous Bone Marrow Mononuclear Cell TransfusionPhase 2 · NCT06629324
- CannabidivarinPhase 2 · NCT03202303
- DiphenhydraminePhase 2 · NCT05501678
- Drug: NV01-A02Phase 2 · NCT06951854
- Drug: Placebo (ZP8396)Phase 2 · NCT06951854
- DT402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))Phase 2 · NCT07303907
- EpidiolexPhase 2 · NCT04517799
- Escitalopram 10mgPhase 2 · NCT06826326
- EsomeprazolePhase 2 · NCT03866668
- FMT ProtocolPhase 2 · NCT07105267
- Folinic AcidPhase 2 · NCT02839915 · NCT07642661 · NCT07630506
- Full Spectrum MicrobiotaPhase 2 · NCT03408886
- Ganaxolone (Ztalmy)Phase 2 · NCT07635862
- ILT-101 ld-(IL2)Phase 2 · NCT07589842
- KZ101Phase 2 · NCT06866275
- L-carnitinePhase 2 · NCT07216001
- Levoleucovorin CalciumPhase 2 · NCT04060030 · NCT04060017
- Lief Smart PatchPhase 2 · NCT07812233
- Matched PlaceboPhase 2 · NCT03202303
- MB-IMPPhase 2 · NCT06526208
- ML-004 (IR)/(ER) tabletPhase 2 · NCT05889273
- MoviPrepPhase 2 · NCT03408886
- NaCl (0,9%)Phase 2 · NCT07589842
- Omega-DEKPhase 2 · NCT07216001
- Oxytocin nasal sprayPhase 2 · NCT05864508
- Pimavanserin Tartrate 34 Mg ORAL CAPSULE [NUPLAZID]Phase 2 · NCT05999240
- PitolisantPhase 2 · NCT05953389
- PPF3Phase 2 · NCT07893964
- PropranololPhase 2 · NCT07091279
- S. boulardii CNCM (National Collection of Cultures of Microorganisms) I-745Phase 2 · NCT06568588
- SertralinePhase 2 · NCT06081348
- SulforaphanePhase 2 · NCT02677051
- SuvorexantPhase 2 · NCT05546554
- TB006Phase 2 · NCT06500637
- Terpenes-Enriched CBD Oil (THC-Free)Phase 2 · NCT07199218
- Terpenes-Enriched CBD-Predominant OilPhase 2 · NCT07199218
- TTYP01 Tablets (12mg or 18mg)Phase 2 · NCT06757504
- VancomycinPhase 2 · NCT03408886
- vancomycin, Miralax, intestinal microbiotaPhase 2 · NCT04182633
- ZolpidemPhase 2 · NCT05540574
- Autologous MSC isolation, concentration, and cryopreservation of adult mesenchymal stem cellsPhase 1/2 · NCT07546942
- Fecal microbiota transplantationPhase 1/2 · NCT06290258
- hUC-MSC-Exos Nasal SprayPhase 1/2 · NCT07243561
- Use autologous cSVF + MSCs (cryo) for management of autoimmune component, anti-inflammatory and immune modulationPhase 1/2 · NCT07546942
- XenonPhase 1/2 · NCT07435103
- Active LIFUPhase 1 · NCT07225322
- CannabidiolPhase 1 · NCT05015439
- cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cellsPhase 1 · NCT05003960
- Fecal Microbiota TransplantPhase 1 · NCT04630847
- GlutathionePhase 1 · NCT07304440 · NCT07622316
- hBMMSCPhase 1 · NCT07177677
- PsilocybinPhase 1 · NCT06731621
- Umbilical Cord Blood-Derived Stem Cells and ExosomesPhase 1 · NCT07304440 · NCT07622316
- WJMSCPhase 1 · NCT06293950
- PrednisoneEarly phase 1 · NCT06934915
- Psychotropic medication (at discretion of psychiatrist)Early phase 1 · NCT07024303
- VGN-Ex05eEarly phase 1 · NCT07433517
Closest to patients
- Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With thSingle Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With thComplejo Asistencial de Zamora. Hospital Provincial de Zamora · Zamora, Spain + 4 more hospitalsPhase 3Results expected 2026
- Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric PatientsMulticenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric PatientsRichmond Behavioral Associates · Staten Island, United States + 40 more hospitalsPhase 3Results expected 2027
- Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric PatientsMulticenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder in Pediatric PatientsVector Clinical Trials · Las Vegas, United States + 38 more hospitalsPhase 3Results expected 2027
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Randomised trial
Cannabidiol and fronto-parietal EEG connectivity in autistic children.
Cannabidiol and fronto-parietal EEG connectivity in autistic children.
Cerebral cortex (New York, N.Y. : 1991)
PubMed · PMID 42981179Publication
"They'll Show You Their Strengths": Teachers' Transition Praxis for Students.
"They'll Show You Their Strengths": Teachers' Transition Praxis for Students.
Intellectual and developmental disabilities
PubMed · PMID 42981146Publication
Quality and Reliability of YouTube Videos as a Source of Information Regarding Early Signs of Autism Spectrum Disorder.
Quality and Reliability of YouTube Videos as a Source of Information Regarding Early Signs of Autism Spectrum Disorder.
Journal of autism and developmental disorders
PubMed · PMID 42980944Publication
Cognitive profile, autistic traits, visual perception, and visual evoked potential findings in Silver-Russell syndrome.
Cognitive profile, autistic traits, visual perception, and visual evoked potential findings in Silver-Russell syndrome.
Applied neuropsychology. Child
PubMed · PMID 42981150Publication
"Do You Need Something or Am I Just Listening to You?": A Qualitative Content Analysis of Prosody-Related Social Communication Challenges in Autistic Young Adults.
"Do You Need Something or Am I Just Listening to You?": A Qualitative Content Analysis of Prosody-Related Social Communication Challenges in Autistic Young Adults.
Journal of autism and developmental disorders
PubMed · PMID 42980942
Find fellow researchers
Groups with active Autism work.
Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Centre National de la Recherche Scientifique
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Boston Children's Hospital
Boston, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of California, Los Angeles
Los Angeles, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Yale University
New Haven, United States
Team details appear once the team leader joins.
Is this your team? Claim it
King's College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Johns Hopkins University
Baltimore, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Icahn School of Medicine at Mount Sinai
New York, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of Toronto
Toronto, Canada
Team details appear once the team leader joins.
Is this your team? Claim it
University of Pennsylvania
Philadelphia, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Karolinska Institutet
Stockholm, Sweden
Team details appear once the team leader joins.
Is this your team? Claim it